A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot trial.
A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot trial.
复制标题
DOI：
10.1097/jto.0b013e318215a4dc
复制
发表时间：
2011-06
期刊：
影响因子：
--
通讯作者：
Rigotti NA
中科院分区：
文献类型：
--
作者：
Park ER;Japuntich S;Temel J;Lanuti M;Pandiscio J;Hilgenberg J;Davies D;Dresler C;Rigotti NA
Although most smokers diagnosed with lung cancer report that they want to quit smoking, many do not succeed. Smokers who quit when lung cancer is diagnosed have improved treatment efficacy, quality of life, and survival. Effective smoking cessation interventions targeted to thoracic oncology patients are needed. This pilot study examined the feasibility and potential efficacy of a 12-week program that combined smoking cessation counseling with varenicline. 7-day point prevalence tobacco abstinence rates at the end of treatment were compared to a usual care control group. From 01/08-08/09, patients with a diagnosed or suspected thoracic malignancy were recruited at their initial visit to a thoracic surgeon or thoracic oncologist at Massachusetts General Hospital. Of 1130 patients screened, 187 (17%) were current smokers, and an additional 66 (6%) reported quitting within the past 6 months. 116 (67%) of smokers were eligible, and 49 (42%) of eligible smokers enrolled (control group n=17, intervention group n=32). Intervention participants completed a median of 9 counseling sessions; 50% of intervention participants completed the full varenicline course. At 12-week follow-up, biochemically-validated 7-day point prevalence tobacco abstinence rates were 34.4% in the intervention group vs. 14.3% in the control group (OR = 3.14, 95% CI = .59-16.62, p = .18). Our findings support the feasibility and acceptability of this program. At the end of treatment, quit rates were higher in the control group. Further testing is indicated to establish efficacy of this treatment package in a randomized clinical trial.
